To access this element change to forms mode OFF
Grant Award View - GA83505
Adjuvant Tislelizumab plus chemotherapy after post-operative pelvic...
GA ID:
GA83505
Agency:
Department of Health and Aged Care
Approval Date:
14-May-2020
Publish Date:
15-Jun-2020
Category:
Health and Medical Research
Grant Term:
1-Jun-2020 to 31-May-2023
Value (AUD):
$1,633,241.35
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
DoHAC 19/20 1.1 Health Policy Research and Analysis
Grant Program:
2019_MRFF_RCRDUN_Reproductive Cancers_funding_commencing_2020
Grant Activity:
Adjuvant Tislelizumab plus chemotherapy after post-operative pelvic chemoradiation in high risk endometrial cancer: the ADELE study
Purpose:
This clinical trial seeks to improve outcomes for women with high-risk endometrial cancer, who have a significant risk of relapse after standard post-operative treatment with chemotherapy and radiotherapy. The trial will find out if relapse rates can be lowered by adding immunotherapy to current standard therapy. Women will be randomly assigned to receive the new treatment combination or existing standard treatment, then followed up to see if outcomes are improved and what side-effects occur.
GO ID:
GO Title:
MRFF Clinical Trials Activity - RCRDUN Initiative – 2019 Reproductive Cancers Grant Opportunity
Internal Reference ID:
MRF1199834
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
University of Sydney
Recipient ABN:
15 211 513 464
Grant Recipient Location
Suburb:
Camperdown
Town/City:
Camperdown
Postcode:
2050
State/Territory:
NSW
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
NSW
Postcode:
Country:
AUSTRALIA